Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

NCT05564377 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05564377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05564377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
April 7, 2023
Completion date
July 1, 2030
Enrollment
2,900 (estimated)
Sites
483

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, locally advanced malignant solid neoplasm, malignant female reproductive system neoplasm, metastatic her2-negative breast carcinoma, metastatic malignant solid neoplasm, recurrent endometrial carcinoma, recurrent fallopian tube carcinoma, recurrent malignant female reproductive system neoplasm, recurrent malignant solid neoplasm, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma, unresectable her2-negative breast carcinoma, unresectable malignant solid neoplasm